INSIDE: - Medical Device Daily

MONDAY, OCTOBER 3, 2005 BIOWORLD ® FINANCIAL WATCH PAGE 5of 10Company Acquired By Date Date Value Terms/DetailsAcquired* Or Merged With* Announced Completed (M)**(Country; Symbol) (Country; Symbol)Certain assets of Evolva SA* 9/2/05 9/2/05 ND Evolva acquired the pharmaceutical assetsPoalis A/S* (Switzerland) of Poalis; Poalis’ assets in food and flavor(Denmark)chemicals and agriculture were not includedin the dealPyramid Life 7/6/05 9/22/05 $13 Life Therapeutics paid $13M, and assumedBiological Therapeutics $7M in debt; another $5M could be paid ifCorp.* (ASX:LFE) milestones are reachedQuadrant ML Laboratories 6/16/05 7/14/05 £46.7 Combined company name is Innovata plc;Technologies plc (UK; LSE:MLB) (US$85) ML paid £19.5M cash and the rest inLtd.* (UK)shares as part of the 50-50 merger; ML alsopaid £1.85M cash and shares to acquirethe 18.75% interest in Innovata that Biomeddid not already ownScientific Agilent 5/25/05 7/1 1/05 ND Agilent acquired SSI, a provider of scientificSoftware Inc.* Technologies information management solutionsInc. (NYSE:A)Stressgen Assasy 7/12/05 7/12/05 ND Stressgen Bioreagents was spun out ofBioreagents Designs Inc. Stressgen Biotechnologies Corp. in May;Corp.*Ampersand Ventures funded both dealsBioanylitical Qiagen NV 8/1/05 8/8/05 $0.8 Qiagen paid $0.8M up front and could paybusiness of (the Netherlands; another $0.8M if certain milestones areSuNyx GmbH* QGEN) reached for SuNyx, which has nanotechno-(Germany)logy-based sample preparation technologyTranskaryotic Shire 4/21/05 7/27/05 $1.6B Shire paid $37 in cash for each TKT share,Therapies Inc. Pharmaceuticals a premium of 44% to the four-week average(TKTX) Group plc (UK) before the deal was announcedVicuron Pfizer Inc. 6/16/05 9/14/05 $1.9B Pfizer paid $29.10 per share in cash, orPharmaceuticals$1.9B, a 74% premium to the 90-day priceInc. (MICU)before the deal was disclosedXenova Group Celtic Pharma 6/24/05 9/1/05 £26.1 Celtic, a private equity firm, is paying upplc (UK; XNVA) Group (US$48) to £26.1 in notes, cash or a blend of each for(Bermuda)Xenova; separately, Celtic licensed technologyand provided a $20M loan facilityII. PENDING MERGERS AND ACQUISITIONSCompany Acquiring Date Expected Value Terms/DetailsTo Be Acquired* Company* Announced Completion (M)**(Country; Symbol) (Country; Symbol)Aerogen Inc. Nektar 8/15/05 4Q:05 $32 Nektar to pay $8M cash and $24M in stock,(OTC BB:AEGN) Therapeutics but later said it would exercise option to(NKTR)make an all-cash deal, at $0.75 per share.To subscribe, please call BIOWORLD ® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.Copyright © 2005 Thomson BioWorld ® . Reproduction is strictly prohibited.